---
title: "180 Life Sciences Appoints New CEO Amid Leadership Changes"
date: "2025-02-08 06:20:05"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio180 Life Sciences ( (ATNF) )..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1423187486-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

180 Life Sciences ( [(ATNF)](https://www.tipranks.com/stocks/atnf) ) has shared an update.

On February 5, 2025, 180 Life Sciences Corp. amended its Separation and Release Agreement with former CEO James N. Woody, replacing a contingent $50,000 bonus with $60,000 in restricted common stock, which includes voting and sale restrictions. Additionally, on February 4, 2025, the company’s Board appointed Ryan Smith as Lead Independent Director and Blair Jordan as Chief Executive Officer, with Jordan’s annual compensation increased to $240,000, reflecting strategic leadership changes.

**More about 180 Life Sciences**

180 Life Sciences Corp. operates in the biotechnology industry, focusing on the development of therapeutics for inflammatory diseases, fibrosis, and pain. The company is engaged in the research and development of novel drugs and has a notable presence in the biotechnology market.

**YTD Price Performance:** -19.77%

**Average Trading Volume:** 450,344

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** $4.38M

For detailed information about ATNF stock, go to [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/atnf/stock-analysis).

Trending Articles:
------------------

* [Trump Settlement Would “Cripple” Paramount (NASDAQ:PARA)](https://www.tipranks.com/news/trump-settlement-would-cripple-paramount-nasdaqpara)
* [Ford (NYSE:F) Offers a Closer Look at Tariff Impact](https://www.tipranks.com/news/ford-nysef-offers-a-closer-look-at-tariff-impact)
* [New Rumors Emerge About Intel’s (NASDAQ:INTC) Next CEO](https://www.tipranks.com/news/new-rumors-emerge-about-intels-nasdaqintc-next-ceo)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/180-life-sciences-appoints-new-ceo-amid-leadership-changes)
